Caffeine in the Context of Sorafenib Chemotherapy: Insights From Experimental Hepatocarcinogenesis
Journal of Biochemical and Molecular Toxicology · 2026
DOI: 10.1002/jbt.71017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2026. Verfasst von Leticia Cardoso Valente und 5 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Research Unit (UNIPEX), Botucatu Medical School, São Paulo State University (UNESP), Botucatu, SP, Brazil. Hauptthemen laut MEDLINE: Sorafenib, Liver Neoplasms, Carcinoma, Hepatocellular, Caffeine. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo, Universidade Estadual Paulista (PIBIC).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) features a high mortality burden worldwide, highlighting the need for improved therapeutic strategies. Caffeine (CAF), a widely consumed bioactive compound, has been reported to exert chemopreventive effects in HCC, but its interaction with standard therapies remains poorly explored. We investigated whether CAF enhances the antitumor effects of sorafenib (SOR) chemotherapy in preclinical HCC models. C3H/HeJ mice were submitted to diethylnitrosamine (DEN)‐induced hepatocarcinogenesis and treated with CAF (50 mg/kg), SOR (30 mg/kg), or their combination for 3 weeks. C3A+LX2 spheroids and transwell co‐cultures were also exposed to CAF, SOR, or their combination at 1/5 or 1/10 of the half‐maximal effective concentration. The combination of CAF and SOR produced a synergistic reduction in tumor spheroid viability, consistent with the transcriptomic alterations observed, and inhibited HCC cell colony formation. Nonetheless, treatments exerted comparable effects on reducing liver tumor volume and Afp expression in vivo. Although only CAF + SOR reduced serum ALT levels and uniquely downregulated HCC‐related Ccl3 , treatments showed differential and subtle transcriptomic impacts in DEN‐induced hepatocarcinogenesis, with no promoting or additive effects when combined. In summary, while CAF potentiated SOR antitumoral activity in vitro, their combination did not lead to major effects in vivo, eliciting the need for further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Experimental Research Unit (UNIPEX), Botucatu Medical School, São Paulo State University (UNESP), Botucatu, SP, Brazil.
- Botucatu Medical School, São Paulo State University (UNESP), Botucatu, SP, Brazil.
- Department of Structural and Functional Biology, Botucatu Biosciences Institute, São Paulo State University (UNESP), Botucatu, SP, Brazil.
ORCID-Profile: Leticia Cardoso Valente, Guilherme Ribeiro Romualdo
Förderung
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Universidade Estadual Paulista (PIBIC)
Zitieren
APA
Valente, L. C., Silva, J. S. D., Riechelmann-Casarin, L., Romeiro, F. G., Barbisan, L. F., & Romualdo, G. R. (2026). Caffeine in the Context of Sorafenib Chemotherapy: Insights From Experimental Hepatocarcinogenesis. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.71017
Vancouver
Valente LC, Silva JSD, Riechelmann-Casarin L, Romeiro FG, Barbisan LF, Romualdo GR. Caffeine in the Context of Sorafenib Chemotherapy: Insights From Experimental Hepatocarcinogenesis. Journal of Biochemical and Molecular Toxicology. 2026. doi:10.1002/jbt.71017
BibTeX
@article{Valente2026,
author = {Valente, Leticia Cardoso and Silva, Julia Stocco da and Riechelmann-Casarin, Luana and Romeiro, Fernando Gomes and Barbisan, Luís Fernando and Romualdo, Guilherme Ribeiro},
title = {Caffeine in the Context of Sorafenib Chemotherapy: Insights From Experimental Hepatocarcinogenesis},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2026},
doi = {10.1002/jbt.71017}
}
EUVIMED